首页>投融资
Aspect Biosystems
B轮
Aspect Biosystems Ltd is a biotechnology company that developes bioprinted tissue therapeutics to transform how we treat disease.In September 2022, Next Generation Manufacturing Canada (NGen) had announced a $10.5 million contribution to a $34.8 million project led by OmniaBio Inc and partners ExCellThera, MorphoCell Technologies, Aspect Biosystems, and CATTI
基本信息
-
公司全称Aspect Biosystems Ltd
-
类型生物技术研发商
-
产业领域医疗器械、治疗设备
-
公司人数15人以下
-
地址1781 West 75th Avenue VANCOUVER BRITISH COLUMBIA V6P 6P2; CA; Telephone: +16042630502;
-
联系电话(604) 263-0502
-
邮箱info@aspectbiosystems.com
-
成立时间2013-11-19
投融资
-
2025-01-08B轮1.15亿美元Dimension Capital诺和诺德Radical VenturesInnovate BCPallasite VenturesRhino VenturesJDRF T1D Fund
-
2020-01-09A轮2000万美元Rhino VenturesPallasite VenturesRadical Ventures
-
2018-11-15未透露270万美元Western Innovation （WINN） Initiative
-
2018-05-07未透露100万美元Genome BC
-
2017-09-18未透露未透露Pallasite VenturesRising Tide Fund ManagersHedgewoodTom WilliamsRelentless Pursuit PartnersEndure Capital
- 加载更多
相关投融资企业
未公开
Saluda Medical是一家全球医疗设备公司，通过基于诱发复合动作电位（ECAP）的专利Evoke闭环慢性疼痛治疗技术来改变神经调节行业。公司的第一个产品 Evoke®，是一个用于治疗慢性疼痛的闭环脊髓刺激（SCS）系统，全球有超过5.4亿人患有慢性疼痛。
Evoke皆在通过测量和记录每位患者对刺激的独特反应来优化疼痛缓解，然后每天进行数百万次实时调整，以保持一致的治疗水平。
B轮
Aspect Biosystems Ltd is a biotechnology company that developes bioprinted tissue therapeutics to transform how we treat disease.In September 2022, Next Generation Manufacturing Canada (NGen) had announced a $10.5 million contribution to a $34.8 million project led by OmniaBio Inc and partners ExCellThera, MorphoCell Technologies, Aspect Biosystems, and CATTI
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息